The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Improving outcomes in Hodgkin lymphoma
Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses unmet needs in the field of Hodgkin lymphoma (HL), including increasing rates of complete remission. As patients with HL tend to be younger, long-term remission with first-line therapies and minimal adverse events (AEs) is the ideal goal. Strategies such as using PD-1 inhibitors as well as reducing the amount of treatment will potentially optimize patient outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
